Skip to content
Search

Latest Stories

Ibuprofen may not harm Covid-19 patients: Study

There is no evidence for or against the use of anti-inflammatory drugs such as ibuprofen for patients with Covid-19, according to a study which assessed existing studies on other coronavirus strains as well as the limited literature on the current pandemic.

According to researchers, including those from King’s College London, other types of drugs, such as TNF blockers and JAK inhibitors are also safe to use.


The research, published in the open access cancer journal ecancermedicalscience, assessed 89 existing studies on other coronavirus strains such as MERS and SARS, as well as ones on the current pandemic to find out if certain medications used in people already suffering from diseases should be avoided if they were to catch Covid-19.

It said some patients, such as those with cancer, are already given immunosuppressive drugs to lower the body’s immune response or immunostimulant drugs to boost it.

If these patients then catch Covid-19, doctors need to know what medication to use, the researchers explained.

Mieke Van Hemelrijck, a cancer epidemiologist and an author of the study, said: “This pandemic has led to challenging decision-making about the treatment of Covid-19 patients who were already critically unwell.

“In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune suppressive medication.”

While there had been some speculation that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen might make the symptoms worse for some Covid-19 patients, the researchers said they did not find evidence to support this statement.

Study co-author Sophie Papa commented: “Current evidence suggests that low dose prednisolone (a steroid used to treat allergies) and tacrolimus therapy (an immunosuppressive drug given to patients who have had an organ transplant) may have beneficial impact on the course of coronavirus infections.

However, further investigation is needed.”

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less